Skip to main
GENB

GENB Stock Forecast & Price Target

GENB Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Generate Biomedicines is poised for success as a pioneer in AI-driven biotechnology and with multiple promising product candidates in their pipeline. Their promising lead product, GB-0895, is expected to launch in 2029 with potential for additional programs, providing significant revenue potential for the company. However, they also face potential challenges from competition and legal issues, making it important for investors to monitor these factors closely.

Bears say

Generate Biomedicines is a clinical-stage biotech company that utilizes AI technology for drug discovery and development, with three product candidates in its pipeline. While its lead candidate, GB-0895, may have some potential, the company faces significant risks, such as competition from established biologics and other emerging therapies. Additionally, there is uncertainty around regulatory approval, and the company may require additional financing to fund late-stage development. The potential benefits of the company's generative biology platform and the potential for expansion into other therapeutic areas are not included in current valuation and may represent additional upside for the company. Overall, the potential for Generate Biomedicines' success is uncertain, and its stock may be subject to market volatility and pricing limitations due to the ongoing debate around drug pricing.

GENB has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Generate Biomedicines Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Generate Biomedicines Inc (GENB) Forecast

Analysts have given GENB a Strong Buy based on their latest research and market trends.

According to 5 analysts, GENB has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Generate Biomedicines Inc (GENB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.